CVRx, Inc. (CVRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CVRx: Sell-Off Ignores Its True Potential
CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales force restructuring and reimbursement fears, while earnings and revenue estimates remain stable. Current valuation is deeply discounted versus sector peers, despite high-teens revenue growth and clear operating leverage potential as sales ramp up.
CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript
CVRx, Inc. (NASDAQ:CVRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Kevin Hykes - President & CEO Jared Oasheim - CFO Mike Vallie - IR, ICR Healthcare Conference Call Participants Macauley Kilbane - William Blair Nelson Cox - Lake Street Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Operator Good day, everyone, and welcome to today's CVRx Q1 2025 earnings call. At this time, all participants are in a listen-only mode.
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $1.04 per share a year ago.
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVRx Inc: Overreaction Creates Buying Opportunity
CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness.
CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
CVRx (CVRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in CVRx (CVRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript
CVRx, Inc. (NASDAQ:CVRX ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandler Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the CVRx Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.44 per share a year ago.
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?
CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVRx: Impressive Top-Line Growth Seems Priced In
CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution.
